Evaluation the Gene Expression of P27 and SKP2 Genes in Iraqi Women Patients with Breast Cancer
Keywords:
breast cancer, p27and skp2 genes.Abstract
The current experiment has been conducted to evaluate the suppression activity of P27 and SKP2 genes by using qRT- PCR, Blood samples are taken from 60 patients' women with breast cancer to represent patients' group and 40 women without breast cancer to represent control group, the ages of both groups ranged from 30 to more than 50 years in the Al. Diwaniyah General Teaching Hospital in AL-Qadisiya province. Also, ROC curve analysis is used to demonstrate the accuracy and validity of previous parameters in detecting women with breast cancer and to estimate the sensitivity and specificity. The obtained results showed that the control group has showed significantly (p<0.01) effect on gene expression for P27 (10.882-fold change) comparison with patients groups (4.496-fold change), while the results of this study have explained that the gene expression of SKP2 for patients' group have inquired high significant (p<0.01) superiority which is 13.943-fold change compared to 3.494-fold change for control group. The age groups have no significant effect on gene expression for SKP2 and P27 genes. Analysis results of ROC curve for P27 gene expression explain it is a good indicator to detected the actually patients with breast cancer ,whereas the sensitivity and specificity is 81.7 and 22.5% respectively and the cut-off for P27 is less than 6.52 fold change, while the gene expression of SKP2 is non- efficient to detected patients with breast cancer, whereas the cut-off is more than 4.486 fold change ,the sensitivity and the specificity is 63.3 and 20%respectively.
Downloads
References
Alkarain, A., & Slingerland, J. (2003).
Deregulation of p27 by oncogenic signaling
and its prognostic significance in breast
cancer. Breast Cancer Research, 6(1), 1-9.
Bast Jr, R. C., Ravdin, P., Hayes, D. F., Bates,
S., Fritsche Jr, H., Jessup, J. M., ... &
Somerfield, M. R. (2001). 2000 update of
recommendations for the use of tumor markers
in breast and colorectal cancer: clinical practice
guidelines of the American Society of Clinical
Oncology. Journal of clinical oncology, 19(6),
-1878.
Bencivenga, D., Tramontano, A., Borgia, A.,
Negri, A., Caldarelli, I., Oliva, A., ... &
Borriello, A. (2014). P27Kipl serine 10
phosphorylation determines its metabolism
and interaction with cyclin-dependent
kinases. Cell cycle, 13(23), 3768-3782.
Benvidi, A., Dehghani Firouzabadi, A.,
Dehghan Tezerjani, M., Moshtaghiun, S. M.,
Mazloum-Ardakani, M., & Ansarin, A. (2015).
A highly sensitive and selective
electrochemical DNA biosensor to diagnose
breast cancer. Journal of Electroanalytical
Chemistry, 750, 57—64.
Brown, I., Shalli, K., McDonald, S. L., Moir,
S. E., Hutcheon, A. W., Heys, S. D., &
Schofield, A. C. (2004). Reduced expression of
p27 is a novel mechanism of docetaxel
resistance in breast cancer cells. Breast cancer
research, 6(5), 1-7.
Cai, Z., Moten, A., Peng, D., Hsu, C. C., Pan,
B. S., Manne, R., ... & Lin, H. K. (2020,
December). The Skp2 pathway: a critical target
for cancer therapy. In Seminars in cancer
biology (Vol. 67, pp. 16-33). Academic Press.
Carrano, A. C., Eytan, E., Hershko, A., &
Pagano, M. (1999). SKP2 is required for
ubiquitin-mediated degradation of the CDK
inhibitor p27. Nature cell biology, 1(4), 193-
Catzavelos, C., Bhattacharya, N., Ung, Y. C.,
Wilson, J. A., Roncari, L., Sandhu, C., ... & Slingerland, J. M. (1997). Decreased levels of the
cell-cycle inhibitor p27 Kipl protein: prognostic
implications in primary breast cancer. Nature
medicine, 3, 227-230.
Catzavelos, C., Bhattacharya, N., Ung, Y. C.,
Wilson, J. A., Roncari, L., Sandhu, C., ... &
Slingerland, J. M. (1997). Decreased levels of the
cell-cycle inhibitor p27 Kipl protein: prognostic
implications in primary breast cancer. Nature
medicine, 3, 227-230.
Cavallaro, S., Paratore, S., de Snoo, F.,
Salomone, E., Villari, L., Buscarino, C.,
Ferraii, F., Banna, G., Furci, M., Strazzanti,
A., Cunsolo, R., Pezzino, S., Gangi, S.and
Basile, F. (2012). Genomic analysis: toward a
new approach in breast cancer management.
Crit. Rev. Oncol. Hematol., 81: 207-223
Chander, H., Halpern, M., Resnick
Silverman, L., Manfredi, J. J., & Germain, D.
(2010). Skp2B attenuates p53 function by
inhibiting prohibitin. EMBO reports, 11(3),
-225.
Chappuis, P. O., Kapusta, L., Begin, L. R.,
Wong, N., Brunet, J. S., Narod, S. A., ... &
Foulkes, W. D. (2000). Germline BRCA1/2
mutations and p27Kipl protein levels
independently predict outcome after breast
cancer. Journal of clinical oncology, 18(24),
-4052.
Coats, S., Flanagan, W. M., Nourse, J., &
Roberts, J. M. (1996). Requirement of
p27Kipl for restriction point control of the
fibroblast cell cycle. Science, 272(5263), 877-
Dahia, P. L., Aguiar, R. C., Honegger, J.,
Fahlbush, R., Jordan, S., Lowe, D. G., ... &
Grossman, A. B. (1996). Mutation and
expression analysis of the p27/kipl gene in
corticotrophin-secreting
tumours. Oncogene, 16(1), 69-76.
Gstaiger, M., Jordan, R., Lim, M.,
Catzavelos, C., Mestan, J., Slingerland, J., &
Krek, W. (2001). Skp2 is oncogenic and
overexpressed in human cancers. Proceedings
of the National Academy of Sciences, 98(9),
-5048.
Haas JS. (2005). Evaluation and outcomes of
women with a breast lump and a normal
mammogram result. J Gen Intern Med
Aug;20(8):692-6.
Habeeb,B.M.(2022). Association of ATM and
TGF 1 Genes with Breast Cancer under
Radiotherapy in a Sample of Iraqi Women
Han, S., Park, K., Kim, H. Y., Lee, M. S.,
Kim, H. J., & Kim, Y. D. (1999). Reduced
expression of p27Kipl protein is associated
with poor clinical outcome of breast cancer
patients treated with systemic chemotherapy
and is linked to cell proliferation and
differentiation. Breast cancer research and
treatment, 55, 159-165.
Hengst, L., & Reed, S. I. (1996).
Translational control of p27Kipl
accumulation during the cell
cycle. Science, 271(5257), 1861-1864.
Heravi Karimovi, M., Pourdehqan, M., Jadid
Milani, M., Foroutan, S. K., & Aieen, F. (2006).
Study of the effects of group counseling on
quality of sexual life of patients with breast
cancer under chemotherapy at Imam Khomeini
Hospital. Journal of mazandaran university of
medical sciences, 16(54), 43-51.
Hermeking, H., Lengauer, C., Polyak, K., He,
T. C., Zhang, L., Thiagalingam, S., ... &
Vogelstein, B. (1997). 14-3-3 is a p53-
regulated inhibitor of G2/M
progression. Molecular cell, 1(1), 3-11.
Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu,
J., & Thun, M. J. (2009). Cancer statistics,
CA: a cancer journal for
clinicians, 59(4), 225-249.
Joyce, C., Rayi, A., & Kasi, A. (2018). TumorSuppressor Genes.
Kamura, T., Hara, T., Kotoshiba, S., Yada,
M., Ishida, N., Imaki, H., ... & Nakayama, K.
I. (2003). Degradation of p57 Kip2 mediated
by SCFSkp2-dependent
ubiquitylation. Proceedings of the National
Academy of Sciences, 100(18), 10231-10236.
Kitagawa, M., Lee, S. H., & McCormick,
F. (2008). Skp2 suppresses p53-dependent
apoptosis by inhibiting p300. Molecular
cell, 29(2), 217-231.
Lee, J. et al. (2009) .The function of p27 KIP1
during tumor development. Exp. Mol. Med.,
, 765-771
Lin, H., Ruan, G. Y., Sun, X. Q., Chen, X. Y.,
Zheng, X., & Sun, P. M. (2019). Effects of
RNAi-induced Skp2 inhibition on cell cycle,
apoptosis and proliferation of endometrial
carcinoma cells. Experimental and
Therapeutic Medicine, 17(5), 3441-3450.
Loda, M., Cukor, B., Tam, S. W., Lavin, P.,
Fiorentinc, M., Draetta, G. F., ... & Pagano,
M. (1997). Increased proteasome-dependent
degradation of the cyclin-dependent kinase
inhibitor p27 in aggressive colorectal
carcinomas. Nature medicine, 3(2), 231-234.
Makdissi, F. B. A., Santos, S. S., Bitencourt,
A., & Campos, F. A. B. (2022). An
introduction to male breast cancer for
urologists: epidemiology, diagnosis, principles
of treatment, and special
situations. International braz j urol, 48, 760-
Mamillapalli, R., Gavrilova, N., Mihaylova, V.
T., Tsvetkov, L. M., Wu, H., Zhang, H., & Sun,
H. (2001). PTEN regulates the ubiquitin¬
dependent degradation of the CDK inhibitor
p27KIPl through the ubiquitin E3 ligase
SCFSKP2. Current Biology, 11(4), 263-267.
McCampbell, A. S., Mittelstadt, M. L., Dere,
R., Kim, S., Zhou, L., Djordjevic, B., ... &
Walker, C. L. (2016). Loss of p27 associated
with risk for endometrial carcinoma arising in
the setting of obesity. Current molecular
medicine, 16(3), 252-265.
Park, M. S., Rosai, J., Nguyen, H. T.,
Capodieci, P., Cordon-Cardo, C., & Koff, A.
(1999). p27 and Rb are on overlapping
pathways suppressing tumorigenesis in
mice. Proceedings of the National Academy of Sciences, 96(11), 6382-6387.
Porter, P. L., Malone, K. E., Heagerty, P. J.,
Alexander, G. M., Gatti, L. A., Firpo, E. J., ...
& Roberts, J. M. (1997). Expression of cell¬
cycle regulators p27 Kipl and cyclin E, alone
and in combination, correlate with survival in
young breast cancer patients. Nature
medicine, 3, 222-225.
Radke, S., Pirkmaier, A., & Germain, D.
(2005). Differential expression of the F-box
proteins Skp2 and Skp2B in breast
cancer. Oncogene, 24(21), 3448-3458.
Rivard, N., L'Allemain, G., Bartek, J., &
Pouyssegur, J. (1996). Abrogation of p27Kipl
by cDNAantisense suppresses quiescence (GO
state) in fibroblasts. Journal of Biological
Chemistry, 271(31), 18337-18341.
Russo, A. A., Jeffrey, P. D., Patten, A. K.,
Massague, J., & Pavletich, N. P. (1996).
Crystal structure of the p27Kipl cyclindependent-kinase inibitor bound to the cyclin
A—Cdk2 complex. Nature, 382(6589), 325-
Safaee, A., Zeighami, B., Tabatabaee, H. R.,
& Moghimi Dehkordi, B. (2008). Quality of
life and related factors in breast cancer
patients under chemotherapy. Iranian Journal
of Epidemiology, 3(3), 61-66.
Siegel RL, Miller KD, Fuchs HE, Jemal A.
Cancer Statistics, 2021. CA Cancer J Clin.
;71:7-33. Erratum in: CA Cancer J Clin.
;71:359.
Signoretti, S., Di Marcotullio, L., Richardson, A.,
Ramaswamy, S., Isaac, B., Rue, M., ... & Pagano,
M. (2002). Oncogenic role of the ubiquitin ligase
subunit Skp2 in human breast cancer. The Journal
of clinical investigation, 110(5), 633-641.
Singletary, S. E., Allred, C., Ashley, P.,
Bassett, L. W., Berry, D., Bland, K. L, ... &
Greene, F. L. (2003). Staging system for breast
cancer: revisions for the 6th edition of the
AJCC Cancer Staging Manual. Surgical
Clinics, 83(4), 803-819.
Soerjomataram, L, & Bray, F. (2021). Planning for tomorrow: Global cancer
incidence and the role of prevention 2020—
Nature reviews Clinical
oncology, 18(10), 663-672.
Spirin, K. S., Simpson, J. F., Takeuchi, S.,
Kawamata, N., Miller, C. W., & Koeffler, H.
P. (1996). p27/Kipl mutation found in breast
cancer. Cancer Research, 56(10), 2400-2404.
Spss,(2013).statistical pachage of social
science.version22,aplication Guide:copy
Right by spss Inc.USA.
Sung H, Ferlay J, Siegel RL, Laversanne M,
Soerjomataram I, Jemal A, et al. Global cancer
statistics 2020: GLOBOCAN estimates of
incidence and mortality worldwide for 36
cancers in 185 countries. CA Cancer J Clin.
Tan, P., Cady, B., Wanner, M., Worland, P.,
Cukor, B., Magi-Galluzzi, C., ... & Loda, M.
(1997). The cell cycle inhibitor p27 is an
independent prognostic marker in small (Tia, b)
invasive breast carcinomas. Cancer
research, 57(7), 1259-1263.
Traub, F., Mengel, M., Liick, H. J., Kreipe,
H. H., & von Wasielewski, R. (2006).
Prognostic impact of Skp2 and p27 in human
breast cancer. Breast cancer research and
treatment, 99, 185-191.
Tsuchiya, A., Zhang, G. J., & Kanno, M.
(1999). Prognostic impact of cyclin
dependent kinase inhibitor p27kipl in node
positive breast cancer. Journal of surgical
oncology, 70(4), 230-
VigBetto, G., Motti, M. L., & Fresco, A (2002).
Understanding p27kipl deregulation in cancer:
downregulation or mislocalizaiton?. Cell cycle, 1(6),
-400.Visvader, J. E„ & Stingl, J. (2014).
Mammary stem cells and the differentiation
hierarchy: current status and perspectives. Genes &
development, 28(11), 1143-1158.
Wang, Z., Fukushima, H., Inuzuka, H., Wan, L.,
Liu, P., Gao, D., ... & Wei, W. (2012). Skp2 is a
promising therapeutic target in breast
cancer. Frontiers in oncology, 1, 57.
World Health Organization ,2020.Estimated
of the new cases in 2020,worldwide New
Global Cancer Data.(WHO,2020).
Zhang, W., Cao, L., Sun, Z., Xu, J., Tang, L., Chen, W., ... & Guan, X. (2016). Skp2 is over¬ expressed in breast cancer and promotes breast cancer cell proliferation. Cell cycle, 15(10), 1344-1351.
Zhang, W., Luo, J., Chen, F., Yang, F., Song, W., Zhu, A., & Guan, X. (2015). BRCA1 regulates PIG3-mediated apoptosis in a p53- dependent manner. Oncotarget, 6(10), 76O8.Zhang, W,, Cao, L,, Sun, Z., Xu, J,, Tang, L., Chen, W., ... & Guan, X. (2016). Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation. Cell cycle, 15(10), 1344-1351.
Zweignd, M.H.,campbell.G.(1993). Receiver operating characteristic (ROC) plots : a fundamental evaluation too in clinical medicine. clinical chemistry.,39:561-577.
Downloads
Published
Issue
Section
License
You are free to:
- Share — copy and redistribute the material in any medium or format for any purpose, even commercially.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
